Trevi Therapeutics (TRVI) Cash & Current Investments (2018 - 2026)

Trevi Therapeutics has reported Cash & Current Investments for 9 years, with the latest figure at $171.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 66.36% year-over-year to $171.8 million; the trailing twelve-month figure through Mar 2026 stood at $171.8 million (up 66.36% YoY), and the FY2025 full-year result was $188.3 million, up 74.93% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $171.8 million, down from $188.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $203.9 million in Q2 2025, with the low at $11.6 million in Q1 2022.
• Average Cash & Current Investments over 5 years is $111.2 million, with a median of $103.3 million recorded in 2025.
• Year-over-year, Cash & Current Investments tumbled 72.12% in 2022 and soared 860.03% in 2023.
• Tracing TRVI's Cash & Current Investments over 5 years: stood at $120.5 million in 2022, then slumped by 31.15% to $83.0 million in 2023, then advanced by 29.71% to $107.6 million in 2024, then surged by 74.93% to $188.3 million in 2025, then dropped by 8.75% to $171.8 million in 2026.
• The last three Cash & Current Investments figures came in at $171.8 million (Q1 2026), $188.3 million (Q4 2025), and $194.9 million (Q3 2025), per Business Quant data.

Peer Comparison